P. Jain

发表

TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

Rashmi Kanagal-Shamanna, Koichi Takahashi, Jorge Cortes, 2016, Cancer.

Advances in the clinical staging of chronic lymphocytic leukemia.

K. Rai, P. Jain, 2011, Clinical chemistry.

Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis

H. Kantarjian, J. Cortes, P. Jain, 2013, Current Treatment Options in Oncology.

Malignancy‐associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Cancer.

Prospective Analysis: Relative Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2015, The Lancet. Haematology.

Clinical characteristics of Philadelphia positive T‐cell lymphoid leukemias—(De novo and blast phase CML)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2017, American journal of hematology.

Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia

P. Jain, S. O'brien, 2013, Expert opinion on biological therapy.

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, Haematologica.

Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes

N. Chiorazzi, K. Rai, P. Jain, 2015, Immunologic research.

Phase I/II study of high dose pomalidomide with G‐CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma

Michael L. Wang, P. Jain, R. Orlowski, 2020, American journal of hematology.

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy

C. Flowers, E. Shpall, A. Futreal, 2021 .

Overview of recent developments in chronic lymphocytic leukemia

K. Rai, P. Jain, 2012, South Asian Journal of Cancer.

An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma.

S. Verstovsek, P. Jain, R. Orlowski, 2012, Clinical lymphoma, myeloma & leukemia.

Autologous stem cell transplantation for untreated transformed indolent B‐cell lymphoma in first remission: an international, multi‐centre propensity‐score‐matched study

C. Flowers, P. Jain, C. Tam, 2020, British journal of haematology.

Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma.

P. Jain, J. Khoury, C. Pinnix, 2019, Blood advances.

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.

Z. Estrov, H. Kantarjian, J. Cortes, 2016, Blood.

Haematological cancer: Richter's transformation in CLL—a distinct lymphoma

K. Young, P. Jain, 2014, Nature Reviews Clinical Oncology.

FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia

Z. Estrov, H. Kantarjian, P. Jain, 2014, Cancer.

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

M. Konopleva, H. Kantarjian, J. Cortes, 2015, The Lancet. Haematology.

Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phase

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.

H. Kantarjian, J. Cortes, S. Verstovsek, 2015, The Lancet. Haematology.

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

M. Konopleva, H. Kantarjian, T. Kadia, 2014, Leukemia.

Richter's Transformation in Chronic Lymphocytic Leukemia Richter's Transformation in Chronic Lymphocytic Leukemia

P. Jain, S. O'brien, Susan O 'brien, 2022 .

Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.

C. Flowers, Linghua Wang, Xuelin Huang, 2022, The Lancet. Oncology.

Zanubrutinib in lymphoproliferative disorders: a comprehensive review

P. Jain, Yucai Wang, Michael Wang, 2022, Therapeutic advances in hematology.

Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma

Michael L. Wang, C. Flowers, Linghua Wang, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma.

Michael L. Wang, Maria A. Rodriguez, P. Jain, 2020, Blood.

Long‐term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2018, British journal of haematology.

A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis

Z. Estrov, S. Verstovsek, P. Jain, 2017, Blood research.

Richter's syndrome – update on biology and management

P. Jain, M. Keating, S. O'brien, 2014 .

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

The absolute percent deviation of IGHV mutation rather than a 98% cut‐off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

Z. Estrov, H. Kantarjian, J. Cortes, 2018, British journal of haematology.

Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

Z. Estrov, H. Kantarjian, P. Jain, 2017, Cancer.

Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma.

Lin Pei, K. Patel, K. Young, 2013, Clinical lymphoma, myeloma & leukemia.

Constitutive Phosphorylation of STAT3 by the CK2–BLNK–CD5 Complex

Z. Estrov, D. Harris, P. Jain, 2017, Molecular Cancer Research.

Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia.

Z. Estrov, P. Jain, M. Keating, 2014, Blood.

Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.

Z. Estrov, H. Kantarjian, S. Verstovsek, 2012, Blood.

DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia

Z. Estrov, S. Verstovsek, K. Patel, 2016, Leukemia & lymphoma.

Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes

H. Kantarjian, J. Cortes, S. Verstovsek, 2016, British journal of haematology.

Analysis of long term responses and their impact on outcomes in patients with chronic phase CML treated with four different TKI modalities – analysis of 5 prospective clinical trials

H. Kantarjian, J. Cortes, S. Verstovsek, 2016 .

Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.

H. Kantarjian, J. Cortes, P. Jain, 2015, The Lancet. Haematology.

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Haematologica.

Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

A. Rosenwald, N. Chiorazzi, K. Rai, 2012, Haematologica.

STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, P. Jain, 2018, Oncotarget.

Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)

Z. Estrov, H. Kantarjian, J. Cortes, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia

Z. Estrov, H. Kantarjian, P. Jain, 2016, Clinical Cancer Research.

Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides

P. Jain, M. Duvic, Eric M Fountain, 2018, Leukemia & lymphoma.

Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B‐cell acute lymphoblastic leukemia (B‐ALL) with TET2 and TP53 mutations

Z. Estrov, P. Jain, N. Daver, 2016, American journal of hematology.

Outcome of patients with therapy-related acute myeloid leukemia with or without an antecedent history of myelodysplasia

G. Garcia-Manero, J. Cortes, T. Kadia, 2017 .

Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma

M. Konopleva, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

Clinical characteristics and outcomes of previously untreated patients with adult onset T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma with hyper‐CVAD based regimens

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, American journal of hematology.

Concurrent myelodysplasia and monoclonal B lymphocytosis in VEXAS syndrome.

P. Jain, N. Pemmaraju, Huifang Lu, 2022, Leukemia research.

Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?

Z. Estrov, H. Kantarjian, R. Luthra, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma.

Z. Estrov, E. Shpall, A. Wotherspoon, 2013, Clinical lymphoma, myeloma & leukemia.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2013, Blood.

inhibitor modalities diagnosed chronic myeloid leukemia : results with four tyrosine kinase Early responses predict better outcomes in patients with newly

H. Kantarjian, P. Jain, F. Ravandi, 2013 .

Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2019, Leukemia & lymphoma.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.

Susan O'Brien, Nitin Jain, Z. Estrov, 2015, Blood.

Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor–resistant chronic lymphocytic leukemia with disease progression and Richter transformation

Z. Estrov, H. Kantarjian, M. Routbort, 2018, Cancer.

Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors

Michael L. Wang, Y. Oki, P. Jain, 2018, British journal of haematology.

Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015, American journal of hematology.

Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial

C. Cleeland, Z. Estrov, D. Harris, 2017, The Lancet. Haematology.

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?

P. Jain, Yucai Wang, A. Beitinjaneh, 2022, Current Treatment Options in Oncology.

Mantle Cell Lymphoma Involving Tonsils: A Clinicopathologic Study of 83 Cases.

Michael L. Wang, P. Jain, R. Kanagal-Shamanna, 2021, Human pathology.

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients

Michael L. Wang, C. Flowers, Shaojun Zhang, 2020, American journal of hematology.

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Michael L. Wang, Shaojun Zhang, Linghua Wang, 2019, Blood.

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Michael L. Wang, O. Casasnovas, P. Zinzani, 2019, Leukemia.

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts

H. Kantarjian, J. Cortes, P. Jain, 2013, Haematologica.

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.

Z. Estrov, E. Shpall, P. Jain, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.

H. Kantarjian, J. Cortes, S. Verstovsek, 2017, Leukemia research.

Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data.

H. Kantarjian, J. Cortes, P. Jain, 2014, Clinical lymphoma, myeloma & leukemia.

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma

Xianglin L. Du, Michael L. Wang, P. Jain, 2021, Leukemia & lymphoma.

A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma

Jennifer B Dennison, S. Hanash, C. Flowers, 2022, Cell reports. Medicine.

TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma

Michael L. Wang, Heng-Huan Lee, Guangchun Han, 2022, Molecular Cancer.

PET‐positive lymphadenopathy in CLL—Not always Richter transformation

L. Jeffrey Medeiros, Z. Estrov, P. Jain, 2017, American journal of hematology.

Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia

Z. Estrov, P. Jain, Koichi Takahashi, 2015, American journal of hematology.

Late extramedullary recurrence of adult onset Burkitt's lymphoma mimicking peritoneal carcinomatosis

P. Jain, S. O'brien, O. Benjamini, 2013, American journal of hematology/oncology.

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis—TAFRO syndrome

Z. Estrov, S. Verstovsek, K. Patel, 2015, American journal of hematology.

Clinical impact of 5'MYC or 3'MYC gain/loss detected by FISH in patients with aggressive B-cell lymphomas.

P. Jain, Shaoying Li, G. Toruner, 2022, Cancer genetics.

Primary autoimmune myelofibrosis (MF) with high‐grade peripheral T‐cell lymphoma (PTCL) NOS

S. Verstovsek, P. Jain, C. Bueso-Ramos, 2013, European journal of haematology.

Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

Michael L. Wang, P. Jain, R. Kanagal-Shamanna, 2018, British journal of haematology.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2019, Blood advances.

Activation of the B‐cell receptor successively activates NF‐κB and STAT3 in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, P. Jain, 2017, International Journal of Cancer.

Chronic lymphocytic leukemia (CLL)—Then and now

K. Rai, P. Jain, 2016, American journal of hematology.

Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.

Michael L. Wang, Shouhao Zhou, P. Jain, 2020, Blood advances.

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma

Michael L. Wang, T. McDonnell, K. Young, 2021, Modern Pathology.

Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma

Michael L. Wang, C. Flowers, Shaojun Zhang, 2021, Nature Communications.

Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease?

Z. Estrov, P. Jain, M. Keating, 2013, Clinical lymphoma, myeloma & leukemia.

Central nervous system Richter’s transformation and parvovirus B19 infection

Lin Pei, Z. Estrov, T. Kadia, 2013, Leukemia & lymphoma.

Advances in the assessment of minimal residual disease in mantle cell lymphoma

Michael L. Wang, P. Jain, Dayoung Jung, 2020, Journal of Hematology & Oncology.

Novel therapeutic options for relapsed hairy cell leukemia

P. Jain, F. Ravandi, A. Polliack, 2015, Leukemia & lymphoma.

Update on the Biology and Treatment Options for Hairy Cell Leukemia

P. Jain, F. Ravandi, N. Pemmaraju, 2014, Current Treatment Options in Oncology.

Long‐term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial

H. Kantarjian, P. Jain, F. Ravandi, 2016, British journal of haematology.

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

Z. Estrov, H. Kantarjian, P. Jain, 2015, Leukemia & lymphoma.

Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy

Michael L. Wang, C. Flowers, P. Jain, 2020, British journal of haematology.

Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib

Michael L. Wang, C. Flowers, Shaojun Zhang, 2021, American journal of hematology.

Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma

Michael L. Wang, Y. Oki, K. Patel, 2017, British journal of haematology.

Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments

P. Jain, Michael Wang, 2022, American journal of hematology.

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.

Michael L. Wang, C. Flowers, Shaojun Zhang, 2020, Blood advances.

Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management

P. Jain, Michael Wang, 2019, American journal of hematology.

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations

Michael L. Wang, P. Jain, L. Rui, 2023, Blood Cancer Journal.

Blastoid Mantle Cell Lymphoma.

P. Jain, Michael Wang, 2020, Hematology/oncology clinics of North America.

Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia.

Wentian Li, Xiao-Jie Yan, N. Chiorazzi, 2011, Blood.

STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, T. Manshouri, 2021, Oncotarget.

STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells

Z. Estrov, D. Harris, P. Jain, 2018, Oncotarget.

Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells

Z. Estrov, D. Harris, P. Jain, 2015, Molecular Cancer Research.

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner

Michael L. Wang, P. Jain, Yucai Wang, 2022, Current Oncology Reports.

Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia

Z. Estrov, D. Harris, P. Jain, 2018, Leukemia & lymphoma.

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

Z. Estrov, H. Kantarjian, P. Jain, 2016 .

Ibrutinib Disrupts the Metabolic Program of CLL Cells in-Vivo

Z. Estrov, D. Harris, P. Jain, 2016 .

High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome

Z. Estrov, H. Kantarjian, P. Jain, 2015, American journal of hematology.

STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage

Z. Estrov, D. Harris, P. Jain, 2019, The Journal of Immunology.

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

J. Vose, D. Miklos, P. Jain, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

E. Elinav, R. Arora, R. Jenq, 2023, Nature Medicine.

Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium.

D. Miklos, P. Jain, L. Lekakis, 2022, Journal of Clinical Oncology.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

A. Alencar, A. Zelenetz, I. Flinn, 2022, Blood.

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium

Michael L. Wang, J. Vose, D. Miklos, 2021, Blood.

Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2

Michael L. Wang, A. Heimberger, P. Jain, 2020, Journal for ImmunoTherapy of Cancer.

First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL)

T. Kadia, P. Jain, F. Ravandi, 2020, Leukemia & lymphoma.

Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2016, Clinical Lymphoma, Myeloma & Leukemia.

Computer-aided detection of mantle cell lymphoma on 18F-FDG PET/CT using a deep learning convolutional neural network.

Michael L. Wang, Jingfei Ma, H. Macapinlac, 2021, American journal of nuclear medicine and molecular imaging.

Ibrutinib‐associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: An observational study

N. Bogot, P. Jain, A. Kater, 2019, Mycoses.

Ibrutinib: A Risk Factor for Invasive Fungal Infections?

P. Jain, S. Mulligan, Jennifer R. Brown, 2017 .

Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.

H. Kantarjian, J. Cortes, T. Kadia, 2016, Clinical lymphoma, myeloma & leukemia.

Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein–Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia

Z. Estrov, P. Jain, S. Konoplev, 2013, Leukemia & lymphoma.

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma

Michael L. Wang, P. Jain, L. Medeiros, 2020, Haematologica.

CLL progression after one cycle of FCR: Richter's transformation versus EBV‐associated lympho‐proliferation

P. Jain, J. Burger, J. Khoury, 2017, American journal of hematology.

Recent advances in de novo CD5+ diffuse large B cell lymphoma

A. Rosenwald, K. Young, P. Jain, 2013, American journal of hematology.

Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, International Journal of Hematology.

Biclonal IGHV‐4‐34 hairy cell leukemia variant and CLL ‐ successful treatment with ibrutinib and venetoclax

Z. Estrov, P. Jain, R. Kanagal-Shamanna, 2018, American journal of hematology.

A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)

Michael L. Wang, C. Flowers, S. Parmar, 2020 .

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2012 .

The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes

M. Konopleva, G. Garcia-Manero, J. Cortes, 2020, American journal of hematology.

Ten-year follow up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily.

H. Kantarjian, J. Cortes, S. Verstovsek, 2014 .

Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma.

C. Flowers, G. Garcia-Manero, E. Shpall, 2022, Blood cancer discovery.

FDG PET/CT in Malignant Eccrine Spiradenoma.

P. Jain, Michael G. Swaby, Nawid M. Sarwari, 2017, Clinical Nuclear Medicine.

A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

Long-term control of refractory follicular lymphoma after treatment of secondary acute promyelocytic leukemia with arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA)

P. Jain, J. Burger, S. Konoplev, 2018, Blood Research.

Multiple recurrent extra‐medullary relapses of high‐grade diffuse large B‐cell lymphoma presenting in acute leukemic phase

H. Kantarjian, T. Kadia, P. Jain, 2013, American journal of hematology.

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016 .

Disseminated cytomegalovirus-associated hemophagocytic lymphohistiocytosis in an elderly patient

P. Jain, R. Hasbún, N. Nguyen, 2016, Blood research.

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma

P. Jain, C. Pinnix, M. Duvic, 2023, Advances in radiation oncology.

Immune-Depleted Tumor Microenvironment Signature Is Associated with BTK Inhibitor Resistance in Mantle Cell Lymphoma

Michael L. Wang, C. Flowers, P. Jain, 2021, Blood.

MCL Cells in Tumor Microenvironment Impair T-Cell Metabolic Fitness and Effector Function

Michael L. Wang, P. Jain, Lingzhi Li, 2020 .

Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features

K. Young, P. Jain, R. Kanagal-Shamanna, 2023, The American journal of surgical pathology.

High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management.

P. Jain, M. Dreyling, J. Seymour, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, Leukemia & lymphoma.

STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells

Z. Estrov, D. Harris, T. Manshouri, 2022, The Journal of Immunology.

Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2016, Blood.

Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia

Z. Estrov, H. Kantarjian, K. Patel, 2016, American journal of hematology.

era: analysis of patient from six trials.

M. Konopleva, P. Jain, F. Ravandi, 2016 .

Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.

P. Jain, Yucai Wang, Anagha Deshpande, 2022, Drugs of Today.

“Triple hit” SOX11−, MME+, TP53 mutated high‐grade pleomorphic mantle cell lymphoma

P. Jain, Shaoying Li, G. Tang, 2020, American journal of hematology.

Synchronous presentation of intra‐nodal follicular dendritic cell sarcoma and Castleman disease

J. Manning, P. Jain, R. Kanagal-Shamanna, 2017, American journal of hematology.

Philadelphia–positive dimorphic blasts in mixed‐phenotype acute leukemia with TET2 mutation

Z. Estrov, P. Jain, N. Daver, 2016, American journal of hematology.

Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, J. Cortes, 2016, Cancer.

Clonal hematopoiesis by SLIT1-mutated hematopoietic stem cells due to a breakdown of the autocrine loop involving Slit1 in acquired aplastic anemia

O. Casasnovas, M. Taniwaki, P. Zinzani, 2019, Leukemia.

Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance

A. Rosenwald, N. Chiorazzi, K. Rai, 2012, Haematologica.

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.

P. Jain, E. Jacobsen, A. Kater, 2023, Haematologica.

Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial

Michael L. Wang, C. Flowers, P. Jain, 2021, Blood.

ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY

O. Casasnovas, P. Zinzani, P. Jain, 2021, Hematological Oncology.

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Michael L. Wang, P. Zinzani, P. Jain, 2020, Blood.